Skip to main content

Supplement guide

Nicotinamide Riboside: NAD, Human Trials and Safety

NR can raise NAD-related biomarkers. That is different from proving longer life or a useful clinical outcome; human results depend on the population and outcome.

Published by LongevityMate Editorial · Updated 2026-11-02 · 5 minute read

The short answer

What the evidence means

Nicotinamide riboside, or NR, is a precursor the body can use in NAD metabolism. Human studies show that it can raise NAD-related biomarkers, but this does not establish slower aging or longer life. Selected trials have found different functional outcomes, including a large 2026 Parkinson trial that did not show benefit.See reference 1,See reference 3,See reference 4

Original simplified chemical-connectivity drawing of nicotinamide riboside beside its multistep relationship to NAD+; not a measure of aging or clinical benefit.
On this page

Identify the ingredient before the claim

NR is one NAD precursor; it is not a generic name for all products marketed as “NAD boosters.” Nicotinamide riboside chloride is the material assessed in the cited EFSA opinion. An assessment of a defined ingredient under specified uses is not approval of an anti-aging effect or of every product blend. NR, NMN (nicotinamide mononucleotide), nicotinamide and nicotinic acid are distinct ingredients; their amounts and evidence should not be treated as interchangeable.See reference 5

Selected human trials, with their limits

Trial and population
Martens, 2018: 24 middle-aged and older adults
Studied exposure
1,000 mg/day in a crossover study with 6-week periods
Outcome and boundary
NAD-related blood-cell markers increased. This short trial was not a lifespan trial.See reference 1
Trial and population
Dollerup, 2018: 40 men with obesity and insulin resistance
Studied exposure
2,000 mg/day for 12 weeks
Outcome and boundary
No improvement in insulin sensitivity. This result does not establish effects in every other population.See reference 2
Trial and population
NICE, 2024: 90 people with peripheral artery disease
Studied exposure
NR 1,000 mg/day, NR plus resveratrol, or placebo for 6 months
Outcome and boundary
The NR-only arm suggested a walking-distance benefit; a small disease-specific trial, not proof of general rejuvenation.See reference 3
Trial and population
NOPARK, 2026: 410 people randomized with early Parkinson disease
Studied exposure
NR 500 mg twice daily or placebo for 52 weeks
Outcome and boundary
The primary clinical score favoured placebo; the findings did not support NR as a disease-modifying treatment.See reference 4

A biomarker response and a useful outcome are different

Increasing NAD-related markers shows a biochemical response to the intervention. It does not by itself tell us whether someone thinks more clearly, walks farther, avoids illness or lives longer. Those are separate outcomes, measured in different trials.See reference 1,See reference 2,See reference 3

The NICE walking study used a prespecified one-sided screening threshold and called for a larger confirmatory trial. Its preliminary signal should not be presented as settled treatment evidence or as a result in healthy adults.See reference 3

The selected trials above do not demonstrate longer human life. Nor should a result in one disease group be applied to healthy adults as if the participants, outcome and treatment context were the same.See reference 1,See reference 2,See reference 3,See reference 4

Why the October 2026 result matters

NOPARK was a randomized, placebo-controlled phase 3 study. Its primary Parkinson clinical outcome was worse with NR than placebo after 52 weeks. That finding challenges claims built only on earlier small or mechanistic studies; it does not establish that the same effect occurs in healthy people.See reference 4

The abstract also reports fewer serious adverse events in the NR group. That does not cancel the unfavourable primary efficacy result: tolerability, adverse events and improvement in the disease are different questions. This guide summarizes the public abstract and does not claim a full-text reanalysis.See reference 4

Safety evidence has a population, product and time limit

The short Martens trial reported that NR was well tolerated. That is useful information about that study, but it cannot guarantee safety for years of unsupervised use or for people unlike its participants.See reference 1

Do not turn the research amounts into a dose plan. An EFSA safety assessment is specific to the assessed material and conditions; a higher research exposure is not automatically a consumer recommendation. Personal suitability, medicines, pregnancy and medical conditions need an appropriate professional assessment.See reference 5

Questions that make an NR claim easier to assess

Ask which exact ingredient and amount were studied, whether the product contains other active ingredients, and whether the claimed benefit was actually measured in comparable people. A higher NAD measurement is insufficient support for a promise of “reversed aging.” Keep any prescribed treatment separate from supplement marketing.See reference 1,See reference 3,See reference 4,See reference 5

Common questions

Does raising NAD prove that NR slows aging?

No. A change in a biomarker is not a demonstrated change in lifespan or a clinical outcome. The selected human trials cannot support that leap.See reference 1,See reference 2,See reference 3,See reference 4

Does the NOPARK trial prove the same outcome in healthy adults?

No. It is important evidence in people with early Parkinson disease, under that trial protocol. It neither demonstrates a healthy-aging benefit nor establishes the same effect in all other populations.See reference 4

Get the weekly longevity brief

The week's best longevity research in plain English. Free, every Tuesday.

References

  1. 1. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults

    Martens and colleagues, Nature CommunicationsRandomized trial

  2. 2. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men

    Dollerup and colleagues, American Journal of Clinical NutritionRandomized trial

  3. 3. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial

    McDermott and colleagues, Nature CommunicationsRandomized trial

  4. 4. Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial

    Brakedal and colleagues, JAMARandomized trial

  5. 5. Safety of nicotinamide riboside chloride as a novel food and bioavailability of nicotinamide from this source

    EFSA Panel on Nutrition, Novel Foods and Food Allergens, EFSA JournalEvidence review

Editorial transparency

Published by
LongevityMate Editorial
Review
Editorial evidence review (AI-assisted)
Published
Updated

Medical disclaimer

General education only. AI-assisted editorial evidence review is not a qualified clinical assessment. This guide does not diagnose a condition, interpret a personal result, choose treatment or recommend a supplement dose. Discuss testing, symptoms, medicines and supplements with a qualified health professional.